Chronicles of cancer: A history of mammography

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tisagenlecleucel Produces Durable Responses in Relapsed/Refractory DLBCL

Publish date:: August 11, 2019

Key clinical point: Tisagenlecleucel showed positive safety and clinical outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who achieved a complete response after bridging therapy.

Major finding: Tisagenlecleucel rapidly expanded in all 7 patients during the first 28 days after infusion and 5 patients remained progression free for longer than 12 months.

Study details: A post hoc exploratory analysis from the JULIET trial of 7 patients with relapsed/refractory DLBCL without measurable disease prior to receiving tisagenlecleucel therapy.

Disclosures: The study was funded by Novartis. The authors reported financial affiliations with Novartis and several other companies.

Citation:

Bishop MR et al. Blood Adv. 2019 Jul 23;3(14):2230-6. doi: 10.1182/bloodadvances.2019000151

This Week's Must Reads

Elotuzumab-based therapy may benefit post-transplant response in multiple myeloma,

BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients,

Many children with COVID-19 present without classic symptoms,

System provides ‘faster, less invasive’ method for breast cancer detection,

Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy,

Must Reads in DLBCL

Oral selinexor induced durable responses on relapsed or refractory DLBCL patients,

Despite high organ toxicity, CD19 CART T cell therapy shows low nonrelapse mortality,

Exosomal CA1 may predict chemotherapeutic efficacy in DLBCL,

Hematopoietic stem cell transplantation should be offered to HIV+ patients with lymphoma,

Machine learning provides prognostic indicators for DLCBL recurrence,